Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia

Christoph Kornauth; Charles Herbaux; Bernd Boidol; Chantal Guillemette; Patrick Caron; Marius E. Mayerhöfer; Stéphanie Poulain; Olivier Tournilhac; Tea Pemovska; Stephen J.F. Chong; Emiel Van Der Kouwe; Lukas Kazianka; Georg Hopfinger; Daniel Heintel; Roland Jäger; Markus Raderer; Ulrich Jäger; Ingrid Simonitsch-Klupp; Wolfgang R. Sperr; Stefan Kubicek; Matthew S. Davids; Philipp B. Staber

Journal ArticleOPEN ACCESS

Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia

Haematologica (2021) 106(8) 2251-2256

DOI: 10.3324/haematol.2020.271304

9Citations

9Readers

Cite

CITATION STYLE

APA

Kornauth, C., Herbaux, C., Boidol, B., Guillemette, C., Caron, P., Mayerhöfer, M. E., … Staber, P. B. (2021). Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia. Haematologica, 106(8), 2251–2256. https://doi.org/10.3324/haematol.2020.271304

Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia

Cite

Register to see more suggestions